Journal · Longevity
Telomeres and Batteries: What Epitalon and NAD+ Are Actually Doing
The short answer
Epitalon and NAD+ get mentioned in the same breath so often that people assume they do similar things. They do not. One is aimed at how cells age; the other at whether they have the energy to function at all. The research behind them has different shapes too, and both are more interesting than the marketing.
Questions this article answers
Two different problems
Ageing is not one process, and the compounds aimed at it are not interchangeable. The Longevity Map (pp. 53–55) organises them by what they actually target and tiers them by evidence rather than by popularity, which produces a very different ranking from the one the supplement market offers.
Epitalon addresses cellular ageing: the question of how many times a cell can divide and what happens to gene expression over time.
NAD+ addresses cellular energy: whether the machinery has the cofactor it needs to run at all.
A cell can be young and exhausted, or well-fuelled and at the end of its replicative life. Those are different failures, and that is the useful way to think about this pair.
Epitalon: four amino acids and the telomerase question
Telomeres are the protective caps on chromosomes, and they shorten each time a cell divides. When they get short enough, the cell stops dividing. Telomerase is the enzyme that rebuilds them, and in most adult cells it is largely switched off.
Epitalon is a four-amino-acid peptide, Ala-Glu-Asp-Gly, modelled on a pineal gland extract developed in Russia. A 2003 study in Bulletin of Experimental Biology and Medicine reported that it induced telomerase activity and lengthened telomeres in cultured human cells (reference 1), and a follow-up reported cells dividing beyond their usual limit (reference 2).
Those are laboratory results in cultured cells, and they are the reason anyone became interested in a four-amino-acid peptide in the first place: a mechanism that reaches the enzyme almost nothing else reaches.
The human data is unusual and worth knowing about. A fifteen-year follow-up of elderly patients given the pineal preparation, published in 2011, reported reduced mortality in the treated group (reference 3). Fifteen years is a remarkable length of follow-up for any intervention. It also comes from the same research group that developed the compound, which is the limitation that goes with it.
What epitalon has, then, is a long and internally consistent record from essentially one research programme: decades of results pointing the same way, still waiting on an independent group to run the same experiments. Our epitalon profile goes through the whole picture, including the one caution the mechanism deserves.
NAD+: the cofactor everything else runs on
NAD+ is a coenzyme, not a peptide. Every cell uses it to carry electrons through the reactions that turn food into energy, and the sirtuins and PARP enzymes that maintain DNA consume it to do their work. When NAD+ is scarce, repair and energy production compete for what is left.
Levels fall with age. That decline is not controversial, and it is why supplementing precursors is a plausible idea rather than an invention.
Taking NAD+ directly does not work well, so the approach is to supply a precursor: NR (nicotinamide riboside) or NMN. Both raise blood NAD+ in people, reliably and measurably. That part is settled.
What follows from the rise is the part still being mapped. A randomised placebo-controlled trial of NR in older adults with mild cognitive impairment was published in GeroScience in 2024 (reference 4), and a phase-II randomised pilot in older adults appeared in Alzheimer’s & Dementia in 2026 (reference 5). Real trials, in the right population, measuring real effects — which is the normal shape of early clinical work in healthy ageing, and the groundwork anything larger has to be built on.
The clearer signals turn up where there is a specific deficit. A 2025 double-blind trial in Aging Cell studied nicotinamide riboside in Werner syndrome, a genetic condition of accelerated ageing (reference 6). Mechanisms often show themselves first in the population that has the defect.
The gap between a measurement and an outcome
This is the pattern worth taking away, because it applies far beyond these two compounds.
With NAD+, a number moves reliably. Blood NAD+ goes up. That is a biomarker — a signal that the pathway is responding, which is the first thing anyone would want to see. What that rise translates into day to day is the next question along, and it is the one the trials are working through now.
With epitalon it runs the other way round. The outcome itself was measured — mortality across fifteen years, which almost nothing in this field has ever attempted — and what the literature is still waiting on is a second group running the same experiment.
Neither pattern is a mark against the compound. The toxicology on both has stayed quiet across decades of use, and that is its own kind of evidence — not a small one, and not one every compound in this category can claim. What is worth being clear about is which of the two claims you are leaning on, because they are different claims, and knowing which is which is what lets you judge whether either one answers a question you actually have.
Where they sit against everything else
The Longevity Map treats the energy layer as foundational, and our article on the cellular battery problem goes through why: repair is expensive, and a cell short of energy cannot pay for it. That is the argument for assessing the NAD+ layer before adding compounds that ask cells to do more work.
- NAD+ is the fuel. Established decline, reliable raise, modest measured outcomes.
- SS-31 repairs the machinery that burns the fuel, and became an approved medicine in 2025 for one rare mitochondrial disease.
- MOTS-c changes the instructions cells are following about how to use fuel.
- Epitalon operates at a different level entirely: gene expression and replicative ageing.
Four compounds, four distinct failures. The habit of stacking them because they all appear under the word longevity is how people end up spending a great deal of money without ever identifying which problem they had.
Where that leaves the pair
The biology behind each one is real and well described, and they are aimed at genuinely different failures. What is still being filled in is the clinical picture in healthy people, and it is being filled in differently for each.
If you are going to engage with this category, the useful question is not which compound to buy. It is whether you have done the due diligence to make an informed decision about engaging it at all: what your baseline looks like, what else you are taking, what you would measure along the way, and what would tell you to stop.
Which of the two is worth anything to a given person depends on which problem they actually have, and that is the sort of thing a clinician who can see your baseline is in a position to help sort out.
Questions people ask
Does epitalon lengthen telomeres in humans?
The telomerase and telomere-lengthening findings come from cultured human cells, not from people (references 1, 2). The human research is a fifteen-year follow-up reporting reduced mortality (reference 3), which does not measure telomeres directly and comes from the group that developed the compound.
Does NAD+ supplementation actually work?
Blood NAD+ rises reliably with NR or NMN; that part is well established. Clinical effects in otherwise healthy people have been modest in randomised trials, with clearer signals in populations that have a specific deficit (references 4, 5, 6).
NR or NMN: which should I take?
NR has the longer human trial record. NMN sits one step closer to NAD+ in the pathway and has the more recent trials. Our NAD+ profile covers the differences, including availability.
Can you take epitalon and NAD+ together?
They work on different problems, so there is no mechanistic conflict between them. Which of the two problems you have is the question that comes first.
Why not just take NAD+ itself?
Oral NAD+ is largely broken down before it reaches cells, so the working approach is to supply a precursor the cell can convert: NR or NMN. Both raise blood NAD+ measurably.
Why are these compounds grouped together at all?
Mostly by the word longevity. NAD+ is the fuel, SS-31 repairs the machinery that burns it, MOTS-c changes the instructions for using it, and epitalon works at the level of gene expression and replicative ageing. The Longevity Map (pp. 53–55) sorts the category by what each one targets.
Where this comes from in our books
This article is the plain-language version. The book sections below go further, with full mechanism detail, evidence tiers and how each idea fits a complete protocol. Page numbers refer to the print editions.
Read next
Put the framework to work
The free Protocol Builder applies the same category-first logic as the books, built from the same compound database.
Open the Protocol BuilderSee the book seriesReferences
- Khavinson VKh, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590–592. View source
- Khavinson VKh, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503–506. View source
- Korkushko OV, Khavinson VKh, Shatilo VB, Antonyk-Sheglova IA. Peptide geroprotector from the pituitary gland inhibits rapid aging of elderly people: results of 15-year follow-up. Bull Exp Biol Med. 2011;151(3):366–369. View source
- A randomized placebo-controlled trial of nicotinamide riboside in older adults with mild cognitive impairment. GeroScience. 2024;46(1):665–682. View source
- Martens CR, Decker KP, DeConne TM, et al. A phase-II randomized controlled pilot study of nicotinamide riboside supplementation in older adults. Alzheimers Dement. 2026;22(7):e71605. View source
- Shoji M, Kato H, Koshizaka M, et al. Nicotinamide riboside supplementation benefits in patients with Werner syndrome: a double-blind trial. Aging Cell. 2025;24(8):e70093. View source
How this article is maintained. Research and regulatory status change. We review our articles against current sources and update them as new information becomes available; the date at the top shows the last review.
Educational information only, not medical advice. Nothing in this article is a recommendation to use any compound or a dosing guide. Talk to a qualified clinician before starting, stopping or combining any compound.